type2diabetes News & Analysis
2 articles
Market Mood
Lilly (LLY) obesity pill reduces cardiovascular risks in trial
Eli Lilly (LLY) announced that its Foundayo obesity pill met its trial goals by reducing the risk of major cardiovascular events by 16% in over 2,700 adults with type 2 diabetes. Compared to insulin glargine, patients taking Foundayo experienced a 57% lower risk of death from any cause. Additionally, those on Foundayo had greater reductions in blood sugar and weight, unlike patients on insulin glargine who gained weight. Eli Lilly plans to seek U.S. approval for Foundayo for type 2 diabetes by the end of Q2.
Read More
GLP-1 Treatment Gaps Increase Heart Risks for Type 2 Diabetes Patients
A recent study reveals that interruptions in GLP-1 treatment for Type 2 diabetes significantly elevate the risks of heart attacks, strokes, and mortality. This finding underscores the critical nature of continuous diabetes management, particularly in a market increasingly focused on chronic care solutions. With diabetes prevalence rising, pharmaceutical companies producing GLP-1 medications may see heightened scrutiny over treatment adherence. The implications for healthcare policy and insurance coverage could also shift, potentially impacting healthcare stocks and related sectors.
Read More